Investors and clinicians will get a close look at 4D Molecular Therapeutics’ lead gene therapy, 4D-150, this fall. The company has locked in October 21, 2026, for its Investor Day in New York City. The spotlight will be on 4D-150’s clinical progress and commercial outlook in treating blinding retinal vascular diseases.
The event starts at 10:30am ET. Attendees can expect a company presentation, retina expert panels, and a live Q&A. 4DMT will stream the event online for those who can’t make it in person. Registration is open on the company’s investor website. The webcast archive will stay up for a full year. The company says the Investor Day will dig into 4D-150’s late-stage clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Both are major causes of vision loss worldwide.
The Phase 3 4SIGHT trial for diabetic macular edema is enrolling 514 treatment-naive patients in a global, randomized, double-masked study, comparing a single intravitreal injection of 4D-150 to aflibercept administered every 8 weeks.
4D-150 is in Phase 3 for both wet AMD and DME. The therapy is built to deliver long-lasting anti-VEGF biologic treatment with just one intravitreal injection. The goal is to cut down on how often patients need treatment for these serious eye conditions. 4DMT says 4D-150 could change how these diseases are managed. But all its products are still investigational. None have FDA or other regulatory approval yet.
Recent trial data looks promising. According to market coverage citing B. Riley, the two-year SPECTRA study at the Phase 3 dose showed patients gained an average of 10.8 letters in best-corrected visual acuity (BCVA). They needed only 5.2 extra injections after three initial aflibercept loading doses. That’s a big deal in the crowded field of retinal gene therapies.
4DMT is also moving forward with 4D-710. The company calls it the first genetic medicine to deliver and express the CFTR transgene in the lungs of people with cystic fibrosis using aerosol delivery. But like 4D-150, 4D-710 is still in clinical or preclinical testing and has not been reviewed by regulators.
Investor access and industry context
Anyone can sign up for the webcast through the company’s site. The archive will stay live for a year. That means investors and clinicians can catch up on the latest updates at any time. The event lands as the biotech sector watches late-stage gene therapy programs for signs of lasting clinical benefit and commercial promise. Ophthalmology Times reporting from EURETINA 2026 notes that the Phase 3 wet AMD program for 4D-150 includes two fully enrolled studies, 4FRONT-1 and 4FRONT-2. Results are due in the first and second halves of 2027.
At EURETINA 2026, company representatives confirmed that, following two-year SPECTRA data, the global Phase 3 program for 4D-150 in diabetic macular edema was launched, and regulatory feedback indicates only one pivotal study is required for DME.
4D Molecular Therapeutics is putting 4D-150 front and center. The company is opening its plans to investors and clinical experts. It wants a leading spot in gene therapy for retinal disease. But the real test is still ahead. Regulatory approval and real-world results will decide if 4DMT’s science pays off for patients and shareholders.
